Table 2.
Seroprevalence of anti-SARS-CoV-2 antibodies, unweighted and weighted with age, in weekly periods 1 and 2
|
Weekly Period 1 (2020.05.25 - 2020.05.30) |
Weekly Period 2 (2020.07.06 - 2020.07.08) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Total case number |
Screening Positive No.* |
Confirmatory Positive no.† |
Unweighted prevalence |
Weighted prevalence |
Total case number |
Screening Positive No.* |
Confirmatory Positive no.† |
Unweighted prevalence |
Weighted prevalence |
|
| Age, years | ||||||||||
| 20-29 | 411 | 0 | 0 | 0•00% | 0•000% | 206 | 0 | 0 | 0•00% | 0•000% |
| 30-39 | 727 | 1 | 1 | 0•01% | 0•021% | 343 | 0 | 0 | 0•00% | 0•000% |
| 40-49 | 1049 | 3 | 1 | 0•01% | 0•015% | 487 | 0 | 0 | 0•00% | 0•000% |
| 50-59 | 1830 | 5 | 1 | 0•01% | 0•008% | 932 | 0 | 0 | 0•00% | 0•000% |
| Young age group (< 60) | 4017 | 9 | 3 | 0•03% | 0•044% | 1968 | 0 | 0 | 0•00% | 0•000% |
| 60-69 | 2551 | 3 | 2 | 0•02% | 0•010% | 1296 | 4 | 2 | 0•04% | 0•020% |
| 70-79 | 1852 | 4 | 1 | 0•01% | 0•003% | 971 | 0 | 0 | 0•00% | 0•000% |
| 80-89 | 1001 | 2 | 0 | 0•00% | 0•000% | 545 | 1 | 1 | 0•02% | 0•005% |
| ≥ 90 | 356 | 1 | 1 | 0•01% | 0•002% | 208 | 1 | 1 | 0•02% | 0•003% |
| Old age group (≥ 60) | 5760 | 10 | 4 | 0•04% | 0•015% | 3020 | 6 | 4 | 0•08% | 0•028% |
| All ages‡ | 9777 | 19 | 7 | 0•07% (0•03-0•15) | 0•06% (0•02-0•12) | 4988 | 6 | 4 | 0•08% (0•02-0•20) | 0•03% (0•00-0•11) |
⁎
Cases positive for Elecsys Anti-SARS-CoV-2 Assay.
†
Cases positive for both Elecsys Anti-SARS-CoV-2 Assay and Academia Sinica ELISA assay.
‡
Prevalence of all ages is shown as percentage with 95% CI; for weekly periods 1 & 2 combined, the total case number is 14,765 with 11 confirmed seropositive cases, and the unweighted prevalence is 0•07% (0•04-0•13) and the weighted prevalence is 0•05% (0•02-0•10).